ATP-competitive p97 inhibitor CB-5339, the successor of CB-5083, is being evaluated in Phase 1 clinical trials for anti-cancer therapy. Different modes of action p97 inhibitors such as allosteric inhibitors are useful to overcome one the major problems of targeted therapy: drug-induced resistance. W...
ORGANISM(S): Homo sapiens (Human)
